A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency-Reference-Cited by-同舟云学术

A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency

Published:2012-11-09 Issue:3 Volume:41 Page:536-540
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Yu Hongbin,Tweedie Donald

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference28 articles.

1. Aromatic Hydrocarbon Binding to Cytochrome P450 and Other Enzyme Binding Sites: Are Hydrophobic Compounds Drawn into the Active Site or Pushed from the Aqueous Phase?

2. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

3. The destruction of cytochrome P-450 by alclofenac: Possible involvement of an epoxide metabolite

4. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”

5. Trainable structure–activity relationship model for virtual screening of CYP3A4 inhibition

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group;Clinical Pharmacology & Therapeutics;2023-12-10

2. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10

3. Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance;Drug Metabolism and Disposition;2023-03-27

4. In Silico Toxicology;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2023

5. Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase;Toxicology and Applied Pharmacology;2021-08